In a research report published Monday, BTIG analyst Dane Leone reiterated a Neutral rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), after the drug maker presented at the American Society of Clinical Oncology (ASCO) the interim data from the Phase 1 TRANSCEND study on JCAR017 in r/r NHL patients. Juno shares are currently trading at $23.44, down $2.77 or -10.57%.

Leone, “The data on 3 months of follow up in the core group showed an ORR of 66% and CR of 50%. The core group represents the population that will move forward into the upcoming pivotal trial, and could serve as a benchmark for expectations of the pivotal dataset. Although we find it difficult to compare Juno’s current dataset to KITE’s ZUMA-1 (KTEC19) since TRANSCEND is more heavily weighted towards TFL patients, we think there could be limited differentiation between the outcomes.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Dane Leone has a yearly average return of 13.6% and a 71% success rate. Leone has a 23% average return when recommending JUNO, and is ranked #226 out of 4579 analysts.

Out of the 14 analysts polled by TipRanks (in the past 12 months), 8 rate Juno Therapeutics stock a Hold, while 6 rate the stock a Buy. With a return potential of 31%, the stock’s consensus target price stands at $31.00.